Kallikrein-4 (11-19)

Kallikrein-4 (11-19) is a synthetic peptide fragment corresponding to amino acid residues 11 through 19 of human kallikrein-related peptidase 4. As a member of the kallikrein peptide family, it represents a bioactive region derived from a serine protease involved in diverse physiological processes, including proteolytic cascades, tissue remodeling, and cellular signaling. The 11-19 segment is of particular interest for researchers investigating the structure-function relationships of kallikrein-4, as well as for those studying peptide-protein interactions, substrate specificity, and enzymatic regulation within the kallikrein-kinin system. Its defined sequence and manageable length make it a valuable tool for biochemical assays, mechanistic studies, and the development of peptide-based probes.

Peptide substrate research: Synthetic fragments such as the 11-19 peptide of kallikrein-4 are widely utilized as model substrates in enzymology. By providing a defined sequence that mimics a native cleavage site, this peptide enables the assessment of proteolytic activity, substrate recognition, and specificity of kallikrein-4 and related proteases. Researchers can monitor hydrolysis events, determine kinetic parameters, and compare the activity of wild-type versus mutant enzymes, thereby elucidating the molecular determinants of substrate processing.

Protein-protein interaction studies: The 11-19 region of kallikrein-4 can serve as a functional probe to investigate direct binding interactions with endogenous inhibitors, cofactors, or receptor proteins. Utilizing this peptide in binding assays, surface plasmon resonance, or co-immunoprecipitation experiments allows researchers to map interaction interfaces, quantify binding affinities, and explore the regulatory mechanisms that govern kallikrein-4 activity within complex biological systems.

Antibody generation and epitope mapping: Short synthetic peptides derived from functionally relevant regions of proteins are commonly employed as immunogens for the production of sequence-specific antibodies. The 11-19 peptide may be conjugated to carrier proteins and used to immunize animals, facilitating the generation of polyclonal or monoclonal antibodies targeting this precise epitope. Such antibodies are invaluable for detection, quantification, and localization studies of kallikrein-4 in various biological samples.

Peptide structure-function analysis: The defined sequence of the 11-19 fragment enables detailed investigations into the conformational preferences and structural motifs of kallikrein-4-derived peptides. Techniques such as circular dichroism spectroscopy, NMR, or molecular dynamics simulations can be applied to examine secondary structure formation, stability, and solvent interactions. Insights gained from these studies inform the rational design of modified peptides with enhanced stability, altered activity, or improved binding characteristics for research applications.

Peptidomimetic and inhibitor development: The 11-19 segment provides a template for the rational design of peptidomimetics and small-molecule inhibitors targeting kallikrein-4 or its interaction partners. By systematically modifying the peptide sequence, incorporating non-natural amino acids, or introducing chemical constraints, researchers can identify lead compounds with improved pharmacological properties for use in biochemical assays, target validation, or mechanistic studies. Such efforts support the broader field of protease research, where selective modulation of enzymatic activity is of central importance for understanding physiological regulation and developing novel research tools.

1. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

2. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs

3. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

5. TMEM16F and dynamins control expansive plasma membrane reservoirs